News

March 9, 2020March 9, 2020

Viral Vector Reformulated for Ovarian Cancer CAR T-cell Therapy, Anixa Says

News

Anixa Biosciences and Moffitt Cancer Center have completed the development and validation of a new viral vector designed to improve the efficacy of their immunotherapy candidate for ovarian cancer, based ... Read more

March 6, 2020March 23, 2020

Women With Low LDL Have Lower Ovarian Cancer Risk, Genetic Analysis Shows

News

Women with naturally lower levels of LDL cholesterol have less risk of ovarian cancer, regardless of mutations in BRCA genes, a genetic analysis study revealed. The findings suggest a role ... Read more

March 5, 2020March 5, 2020

Video: BioNews’ Social Media Campaign Highlights #WhatMakesMeRare

News

In recognition of Rare Disease Day Feb. 29, BioNews Services launched a social media campaign last month asking patients to describe what makes them rare. Running Feb. 7–29, the #WhatMakesMeRare ... Read more

March 4, 2020March 4, 2020

DPX-Survivac Shows Promise in Advanced OC, Early Phase 2 Data Show

News

Treatment with IMV‘s cancer vaccine DPX-Survivac, combined with intermittent low-dose cyclophosphamide, continues to show promise in women with recurrent, advanced ovarian cancer, updated results from a Phase 1/2 trial show. ... Read more

March 2, 2020March 2, 2020

New Blood Test May Aid in Determining Cancerous Ovarian Growths, Study Shows

News

The inflammatory protein interleukin-6 (IL-6) appears at significantly higher levels in the blood of ovarian cancer patients in comparison with women with benign masses in the ovaries and healthy women, ... Read more

February 28, 2020February 28, 2020

COM701 Shows Promise in Treating Ovarian, Other Solid Tumors, Early Data Suggest

News

Treatment with Compugen‘s immune checkpoint inhibitor COM701, either alone or in combination with Opdivo (nivolumab), is well-tolerated in people with advanced solid tumors, including ovarian cancer, early Phase 1 trial results show. ... Read more

February 26, 2020February 27, 2020

Zejula as First-line Treatment for Advanced Ovarian Cancer Before FDA

News

The U.S. Food and Drug Administration (FDA) has accepted GSK‘s request to extend approval for Zejula (niraparib) to include as a first-line maintenance therapy for women with newly diagnosed and ... Read more

February 24, 2020February 24, 2020

University of Sydney Given $3.75M Grant to Study Personalized Ovarian Cancer Treatments

News

The Australian Cancer Council NSW has awarded its annual $3.75 million Translational Program Grant to a University of Sydney research team to explore better ways to personalize ovarian cancer treatments. ... Read more

February 19, 2020February 19, 2020

Myriad Asks FDA to Approve myChoice CDx to Find Potential Lynparza Candidates

News

Myriad Genetics submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of its myChoice CDx test to identify ovarian cancer patients likely to benefit from first-line ... Read more

February 17, 2020February 17, 2020

Analysis of Cells in Fallopian Tube Can Help Classify Ovarian Cancer Subtypes, Study Says

News

Analysis of cells in the fallopian tube, from which most ovarian cancers develop, can help classify ovarian cancer subtypes, with potential implications for cancer prognoses and treatment strategies, a new ... Read more